SCV
CADL icon

Sands Capital Ventures’s Candel Therapeutics CADL Stock Holding History

Sands Capital Ventures’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.18M Hold
405,837
– – 0.68% 22
2026
Q1 		$1.99M Hold
405,837
– – 0.47% 20
2025
Q4 		$2.29M Hold
405,837
– – 0.44% 19
2025
Q3 		$2.07M Hold
405,837
– – 0.45% 19
2025
Q2 		$2.05M Hold
405,837
– – 0.4% 18
2025
Q1 		$2.29M Hold
405,837
– – 0.56% 19
2024
Q4 		$3.52M Hold
405,837
– – 0.77% 18
2024
Q3 		$2.81M Hold
405,837
– – 0.79% 11
2024
Q2 		$2.52M Sell
405,837
-405,900
-50% -$3.05M 0.84% 10
2024
Q1 		$1.28M Hold
811,737
– – 0.31% 12
2023
Q4 		$1.19M Hold
811,737
– – 0.33% 14
2023
Q3 		$747K Hold
811,737
– – 0.22% 16
2023
Q2 		$1.02M Hold
811,737
– – 0.3% 13
2023
Q1 		$1.1M Hold
811,737
– – 0.27% 15
2022
Q4 		$1.45M Hold
811,737
– – 0.4% 16
2022
Q3 		$2.55M Hold
811,737
– – 0.74% 15
2022
Q2 		$2.63M Hold
811,737
– – 0.72% 17
2022
Q1 		$4.13M Hold
811,737
– – 0.86% 16
2021
Q4 		$6.35M Hold
811,737
– – 0.94% 12
2021
Q3 		$8.8M Buy
+811,737
New +$6.73M 1.33% 9

Other funds holding CADL

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sands Capital Ventures's CADL Position: Q2 2026 in Review

Sands Capital Ventures held its Candel Therapeutics (CADL) position steady in Q2 2026 at 405,837 shares worth $4.18M. The position accounts for 0.68% of the portfolio, ranked #22.

Sands Capital Ventures first reported a position in CADL in Q3 2021 and has held it in 20 quarters since. The position peaked at $8.8M in Q3 2021. 128 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Sands Capital Ventures held 405,837 shares of Candel Therapeutics worth $4.18M as of Q2 2026.
  • Sands Capital Ventures left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up 0.68% of Sands Capital Ventures's portfolio in Q2 2026, its #22 holding.
  • Sands Capital Ventures first reported a position in Candel Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Sands Capital Ventures's Candel Therapeutics position peaked at $8.8M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.